DEROSA, LISA
 Distribuzione geografica
Continente #
NA - Nord America 717
EU - Europa 371
AS - Asia 82
AF - Africa 28
OC - Oceania 2
Totale 1.200
Nazione #
US - Stati Uniti d'America 700
IT - Italia 110
SE - Svezia 72
DE - Germania 53
GB - Regno Unito 38
CN - Cina 35
BG - Bulgaria 34
AT - Austria 27
SG - Singapore 20
VN - Vietnam 18
CA - Canada 16
SN - Senegal 13
CI - Costa d'Avorio 12
FI - Finlandia 11
FR - Francia 10
UA - Ucraina 5
IN - India 4
CH - Svizzera 3
NG - Nigeria 3
RU - Federazione Russa 3
AU - Australia 2
HK - Hong Kong 2
NO - Norvegia 2
DK - Danimarca 1
ES - Italia 1
IR - Iran 1
KR - Corea 1
MX - Messico 1
NL - Olanda 1
TR - Turchia 1
Totale 1.200
Città #
Fairfield 93
Houston 79
Woodbridge 72
Ann Arbor 67
Chandler 64
Serra 37
Seattle 36
Ashburn 35
Sofia 34
Wilmington 32
Cambridge 31
New York 24
Vienna 22
Princeton 18
Lancaster 15
Dearborn 14
Ottawa 14
Dakar 13
Frankfurt am Main 13
Lawrence 13
Abidjan 12
Beijing 12
Pisa 12
Dong Ket 11
Florence 11
London 11
Medford 11
Des Moines 10
Nanjing 7
Bremen 6
Milan 6
Spoltore 6
San Diego 5
Düsseldorf 4
Grafing 4
Hefei 4
Phoenix 4
Blackburn 3
Gallarate 3
Lagos 3
Positano 3
Changsha 2
Fremont 2
Guangzhou 2
Hong Kong 2
La Spezia 2
Nanchang 2
Redwood City 2
Canberra 1
Copenhagen 1
Fredrikstad 1
Gallicano 1
Geneva 1
Hanover 1
Hebei 1
Hounslow 1
Izmir 1
Jacksonville 1
Jiaxing 1
Jüchen 1
Kunming 1
Lappeenranta 1
Markham 1
Marseille 1
Massa 1
Messina 1
Mexico City 1
Modena 1
Munich 1
Netherby 1
New Bedfont 1
Ocean View 1
Oslo 1
Pune 1
Ravenna 1
San Francisco 1
Seoul 1
Shenyang 1
Tianjin 1
Toronto 1
Utrecht 1
Viareggio 1
Yellow Springs 1
Totale 923
Nome #
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 174
[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: Preliminary results 146
Feasibility and efficacy of 223Ra-dichloride (223Ra) to treat bone metastases in patients (pts) with castration resistant prostate cancer (mCRPC) 116
Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: Efficacy of octreotide and tamoxifen 102
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients 98
OCTREOTIDE LAR SUITABLE TREATMENT FOR G1-G2 THORACIC NEUROENDOCRINE TUMORS (T-NET): SINGLE CENTER EXPERIENCE 91
null 89
New Prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC). 86
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 82
predictive factors of efficacy of somatostatine analogs (SSA) in gastroenteropancreatic neuroendocrine tumors (GEP-NET) 74
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 57
metastatic well or moderately differentiated Neuroendocrine tumors (WDNET) treated with sequence of different Somatostatin Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): a single center experience 52
EARLY AND COMPLETE CLINICAL RESPONSE TO SUNITINIB IN A PATIENT WITH METASTATIC RENAL CANCER 43
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients 35
Totale 1.245
Categoria #
all - tutte 2.937
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.937


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019108 0 0 0 0 0 0 0 2 4 25 41 36
2019/2020227 35 20 20 20 22 34 19 16 21 7 11 2
2020/202197 4 2 5 2 7 2 0 6 21 24 5 19
2021/2022132 1 5 4 3 28 23 3 4 8 2 4 47
2022/2023252 22 51 22 13 14 29 6 17 55 1 20 2
2023/202496 14 9 22 3 19 20 9 0 0 0 0 0
Totale 1.245